Meagan McGrath is a group leader at the at the Biomedicine Discovery Institute, Monash University, Australia. Her research focuses on skeletal muscle biology, broadly spanning from inherited skeletal muscle disorders called muscular dystrophies and myopathies, as well as muscle metabolism. She is a co-founder of ADAPT-CMD, a clinical and research partnership funded by the Medical Research Futures Fund, aimed at developing a functional genetics platform for advancing personalized treatment of congenital muscle disease – leading the autophagy pipeline of this platform. With specialist expertise bridging both phosphoinositides and autophagy, she also led discoveries identifying the physiological role of the phosphoinositide driven process called autophagic lysosome reformation (ALR). She was the first to identify that ALR is essential to maintain lysosome homeostasis in skeletal muscle, the failure of which causes congenital muscular dystrophy. More recently she has defined an unexpected new role for ALR in whole-body metabolic flexibility and obesity resistance that is independent of the current FGF21 metabolism paradigm.